Insider buying last 90 days
No open-market insider purchases were filed for AVTR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Avantor closed at $15.91 on 9 November 2026, +2.8% on the day. The price sits above both the 50-day ($15.62) and 200-day ($11.30) moving averages, inside a 52-week range of $7.27 to $17.45. The GekkoIndex reads 60.6, in the Accumulation zone, up 1.8 points over five sessions. Gekko Fair Value is $18.05, so the price is 11.9% below it.
The next earnings report is due on 10 February 2027, 87 days away (before open). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 13.7% across the report. Seasonally, the next 20 trading days from this point averaged +1.6% over the last 5 years, rising in 3 of them.
14 firms rate the stock: 2 buy, 11 hold and 1 sell, with a consensus target of $17.35. A typical daily move is about 3.7%, and a typical 20-day move about 5.9%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 9, 2026 close.
Avantor scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Averages disagree
Close $15.54 sits between the 50-day ($15.70) and 200-day ($11.39) averages, or the averages disagree.
See the chart61.7, Accumulation
Reading 61.7 is in the Accumulation zone.
See the GekkoIndex9.8% below
Price is 9.8% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 87 days
Next report Feb 10, 2027, 87 days away — outside a typical 20-trading-day hold.
See earnings+4.9% on average
From this point in the calendar, the next 20 trading days averaged +4.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Avantor closed at $15.54 on Nov 13, 2026, +34.5% over the past year, inside a 52-week range of $7.27 to $17.45.
Use the left and right arrow keys to read daily values.
Put AVTR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Avantor equips labs and production facilities with the materials, tools and expertise they need to operate day to day. Its catalog stretches from high-purity chemicals, reagents and general lab supplies to custom silicone formulations, tailored excipients, single-use assemblies, chromatography resins and columns, sample prep kits, clinical trial kits and fluid handling tips. It also sells instruments like ultra-low-temperature freezers, incubators, biological safety cabinets, evaporators, and systems for filtration and virus inactivation, giving it a footprint that runs from small consumables to larger lab hardware.
On top of these products, Avantor offers services that help customers run their own sites, including on-location lab and production support, clinical services, equipment upkeep, sourcing and procurement help, and assistance developing and scaling biopharmaceutical materials. It works with biopharmaceutical and broader healthcare organizations, schools and universities, government bodies, technology firms, and companies in applied materials. Its reach extends across the Americas, Europe, Asia, and parts of the Middle East and Africa.
The company dates back to 1904 and keeps its headquarters in Radnor, Pennsylvania. Avantor trades on the NYSE under the ticker AVTR.
Avantor’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.7, in the Accumulation zone, down 1.8 points over five sessions.
Down 1.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 80 | −0.9% | −2.1% | ||
| Accumulation (current zone) | 241 | +0.4% | +0.3% | ||
| Neutral | 351 | −0.1% | −0.5% | ||
| Distribution | 28 | −0.7% | +4.8% | ||
| Selling | 2 | Too few readings yet | |||
Average AVTR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Avantor trades 9.8% below Gekko Fair Value of $17.22, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Avantor shares are worth, recalculated every trading day.
$17.22
Gekko Fair Value, Nov 14, 2026
9.8% Undervalued
At the end of Aug 2026 the price was 17.7% below the estimate.
No open-market insider purchases were filed for Avantor, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for AVTR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in AVTR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Avantor has been buying back its own shares.
From company filings.
4of the funds Gekko tracks hold AVTR.
Avantor reports on Feb 10, 2027, before the open (87 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 10, 2027
Expected before the open, 87 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 28, 2026 | $0.22 est $0.21 | $1.70B est $1.64B | −2.6% |
| Jul 29, 2026 | $0.21 est $0.19 | $1.69B est $1.61B | +11.6% |
| Apr 29, 2026 | $0.17 est $0.16 | $1.58B est $1.54B | +3.1% |
| Feb 11, 2026 | $0.22 est $0.21 | $1.66B est $1.64B | −18.1% |
| Oct 29, 2025 | $0.22 est $0.22 | $1.62B est $1.65B | −26.7% |
| Aug 1, 2025 | $0.24 est $0.25 | $1.68B est $1.65B | −15.9% |
| Apr 25, 2025 | $0.23 est $0.23 | $1.58B est $1.61B | −19.4% |
| Feb 7, 2025 | $0.27 est $0.25 | $1.69B est $1.66B | −12.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Avantor is $17.35, +11.6% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Bernstein | — | — |
| Oct 29 | Barclays | $16 | +3.0% |
| Oct 29 | Stifel Nicolaus | $18 | +15.8% |
| Oct 29 | Deutsche Bank | $17 | +9.4% |
| Oct 29 | Stifel Nicolaus | $18 | +15.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Avantor averaged +4.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 3 of 5 |
| Next 10 trading days | +3.1% | 4 of 5 |
| Next 15 trading days | +1.4% | 3 of 5 |
| Next 20 trading days | +4.9% | 3 of 5 |
| Next 30 trading days | +5.4% | 3 of 5 |
For scale, AVTR’s typical 20-trading-day move in either direction is about 5.9%.
Avantor’s market cap is $10.53B, with a P/E ratio of 31.2 and revenue of $6.64B over the last twelve months.
Coverage of Avantor this week reads positive: 2 positive, 2 neutral and 0 negative headlines.
Avantor’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Avantor’s market cap is $10.53B at the Nov 13, 2026 close of $15.54, with 677.6M shares outstanding. The shares trade on a P/E ratio of 31.2.
The consensus analyst 12-month price target for Avantor is $17.35, +11.6% from the last close. Of the 14 firms that rated the stock in the last 90 days, 2 rate it a buy, 11 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Avantor is undervalued: the Nov 13, 2026 close of $15.54 is 9.8% below Gekko Fair Value of $17.22. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Avantor is expected to report on Feb 10, 2027, before the market opens (87 days away). Analysts expect earnings of $0.22 per share on revenue of $1.70B. Avantor beat the earnings estimate in 5 of its last 8 reports, moving 13.7% on average across the report.
Avantor’s 52-week high is $17.45 and its 52-week low is $7.27; it closed at $15.54 on Nov 13, 2026, +34.5% over the past year. Over the last five years the shares peaked at $42.48 on Dec 31, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.